Agios Presents Preclinical Data from Lead Programs at ASH

Agios Pharmaceuticals

today announced that data from its lead programs were highlighted at the American Society of Hematology (ASH) Annual Meeting this week in New Orleans. Two presentations featured in vivo efficacy data in acute myelogenous leukemia (AML) for the company's lead cancer metabolism programs targeting IDH1 and IDH2 mutations. In AML and other cancers, IDH1 and IDH2 mutations initiate and drive cancer growth by blocking maturation of primitive cells. The data presented at ASH demonstrate preclinical single agent and combination efficacy of Agios' IDH mutant inhibitors in patient-derived primary models of AML. Agios also presented